128 related articles for article (PubMed ID: 37218974)
1. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
[No Abstract] [Full Text] [Related]
2. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
[TBL] [Abstract][Full Text] [Related]
4. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.
Sudano I; Krähenbühl S; Mach F; Anstett A; Dhalwani N; Bridges I; Sibartie M; Ray KK
Ther Adv Cardiovasc Dis; 2024; 18():17539447231213288. PubMed ID: 38183273
[TBL] [Abstract][Full Text] [Related]
5. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
Lehrke M; Vogt A; Schettler V; Girndt M; Fraass U; Tabbert-Zitzler A; Bridges I; Dhalwani NN; Ray KK
Adv Ther; 2024 Mar; 41(3):1184-1200. PubMed ID: 38286961
[TBL] [Abstract][Full Text] [Related]
6. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.
Ebenbichler C; Drexel H; Hanusch U; Toplak H; Dhalwani NN; Bridges I; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2024 Feb; 136(3-4):77-86. PubMed ID: 37525072
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study.
Nanchen D; Carballo D; Bilz S; Rickli H; Koskinas KC; Mach F; Mueller C; Crljenica C; Rossi M; Reichert N; Sudano I
Adv Ther; 2022 Jan; 39(1):504-517. PubMed ID: 34796465
[TBL] [Abstract][Full Text] [Related]
8. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
Ray KK; Bruckert E; Peronne-Filardi P; Ebenbichler C; Vogt A; Bridges I; Sibartie M; Dhalwani N
Atherosclerosis; 2023 Feb; 366():14-21. PubMed ID: 36696747
[TBL] [Abstract][Full Text] [Related]
10. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
[TBL] [Abstract][Full Text] [Related]
12. Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study.
Petrov I; Dumitrescu A; Snejdrlova M; Zafrir B; Wożakowska-Kapłon B; Fabryova L; Pintarić H; Bridges I; Petkova R
Adv Ther; 2019 Mar; 36(3):608-620. PubMed ID: 30758746
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
[TBL] [Abstract][Full Text] [Related]
14. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
15. Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.
Al Faraidy K; Akbar M; Shehri M; Aljarallah M; Abdin Hussein G; Dashti R; Al Qudaimi A; Al Nouri F; Awan Z; Essam A; Emara A
PLoS One; 2023; 18(1):e0278821. PubMed ID: 36662739
[TBL] [Abstract][Full Text] [Related]
16. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
Goicoechea M; Álvarez V; Segarra A; Polaina M; Martín-Reyes G; Robles NR; Escudero V; Orellana C; Bea Granell S; de Juan-Ribera J; Fernández Lucas M; Graña JM; Reque J; Sánchez Hernández R; Villamayor S; Górriz JL
Nefrologia (Engl Ed); 2022; 42(3):301-310. PubMed ID: 36210619
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
[TBL] [Abstract][Full Text] [Related]
18. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
19. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
